nach oben

Erschienen in:

10.05.2019 | Original Article

Placental expressions and serum levels of adiponectin, visfatin, and omentin in GDM

verfasst von: Xaynaly Souvannavong-Vilivong, Chantacha Sitticharoon, Roongrit Klinjampa, Issarawan Keadkraichaiwat, Chanakarn Sripong, Saimai Chatree, Rungnapa Sririwichitchai, Tripop Lertbunnaphong

Erschienen in: Acta Diabetologica | Ausgabe 10/2019

Einloggen, um Zugang zu erhalten

Abstract

Aims

Adiponectin, visfatin, and omentin have been shown to be associated with insulin sensitivity and might have a role in the pathophysiology of gestational diabetes mellitus (GDM). This study aimed to (1) compare adiponectin, visfatin, and omentin mRNA expressions in placenta and their serum levels between normal pregnancy (NP) and GDM class A1 (GDMA1) pregnancy and (2) determine correlations between placental gene expressions as well as serum levels with maternal and neonatal clinical parameters in all, NP, and GDM subjects.

Methods

NP subjects (n = 37), who had normal medical history during their pregnancies without diagnosis of any abnormalities and GDMA1 subjects (n = 37), who were diagnosed since they had antenatal care, were recruited when they were in labor with a gestational age of at least 34 weeks. Clinical parameters and serum adiponectin, visfatin, and omentin levels were measured in the delivery room.

Results

GDMA1 subjects had higher serum visfatin and plasma glucose levels, but lower serum omentin levels (p < 0.05 all) compared to controls, with comparable levels of placental adiponectin, visfatin, and omentin expressions, plasma insulin, and indices of insulin sensitivity and insulin resistance. Serum visfatin was negatively correlated with neonatal weight and length in the GDM group (p < 0.05 all). Serum omentin was negatively correlated with pre-pregnancy body mass index and waist circumference only in the NP group (p < 0.05 all). Serum adiponectin was negatively correlated with maternal age and HOMA-IR in the NP group (p < 0.05 all) and with placental weight and serum omentin in the GDM group (p < 0.05 all).

Conclusions

In conclusion, in GDMA1, increased serum visfatin, which has insulin-mimetic effect, might be associated with a compensatory mechanism that improves the impaired insulin function. Decreased serum omentin in GDMA1, which is normally found in visceral obesity, might lead to insulin resistance and contribute to the pathophysiology of GDM.

Kane SC, Costa Fda S, Brennecke S (2014) First trimester biomarkers in the prediction of later pregnancy complications. Biomed Res Int 2014:807196CrossRefPubMedPubMedCentral

De Souza LR, Berger H, Retnakaran R et al (2016) First-trimester maternal abdominal adiposity predicts dysglycemia and gestational diabetes mellitus in midpregnancy. Diabetes Care 39(1):61–64CrossRefPubMed

Bluher M (2012) Clinical relevance of adipokines. Diabetes Metab J. 36(5):317–327CrossRefPubMedPubMedCentral

Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF (1995) A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 270(45):26746–26749CrossRefPubMed

Chen J, Tan B, Karteris E et al (2006) Secretion of adiponectin by human placenta: differential modulation of adiponectin and its receptors by cytokines. Diabetologia 49(6):1292–1302CrossRefPubMed

Yamauchi T, Kamon J, Waki H et al (2001) The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7(8):941–946CrossRefPubMed

Sitticharoon C, Nway NC, Chatree S, Churintaraphan M, Boonpuan P, Maikaew P (2014) Interactions between adiponectin, visfatin, and omentin in subcutaneous and visceral adipose tissues and serum, and correlations with clinical and peripheral metabolic factors. Peptides 62:164–175CrossRefPubMed

Derosa G, Fogari E, D’Angelo A et al (2013) Adipocytokine levels in obese and non-obese subjects: an observational study. Inflammation. 36(4):914–920. https://doi.org/10.1007/s10753-013-9620-4 CrossRefPubMed

Weyer C, Funahashi T, Tanaka S et al (2001) Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86(5):1930–1935CrossRefPubMed

10.

Park KG, Park KS, Kim MJ et al (2004) Relationship between serum adiponectin and leptin concentrations and body fat distribution. Diabetes Res Clin Pract 63(2):135–142CrossRefPubMed

11.

Catalano PM, Hoegh M, Minium J et al (2006) Adiponectin in human pregnancy: implications for regulation of glucose and lipid metabolism. Diabetologia 49(7):1677–1685 Epub 2006 May 11 CrossRefPubMed

12.

Lowe LP, Metzger BE, Lowe WL Jr, Dyer AR, McDade TW, McIntyre HD (2010) Inflammatory mediators and glucose in pregnancy: results from a subset of the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study. J Clin Endocrinol Metab 95(12):5427–5434CrossRefPubMedPubMedCentral

13.

Matuszek B, Burska A, Leszczynska-Gorzelak B, Donica H, Nowakowski A (2013) Comparative analysis of adiponectin isoform distribution in pregnant women with gestational diabetes mellitus and after delivery. Acta Obstet Gynecol Scand 92(8):951–959CrossRefPubMed

14.

Xu J, Zhao YH, Chen YP et al (2014) Maternal circulating concentrations of tumor necrosis factor-alpha, leptin, and adiponectin in gestational diabetes mellitus: a systematic review and meta-analysis. Sci World J 2014:926932

15.

Pala HG, Ozalp Y, Yener AS, Gerceklioglu G, Uysal S, Onvural A (2015) Adiponectin levels in gestational diabetes mellitus and in pregnant women without glucose intolerance. Adv Clin Exp Med. 24(1):85–92. https://doi.org/10.17219/acem/38141 CrossRefPubMed

16.

Adeghate E (2008) Visfatin: structure, function and relation to diabetes mellitus and other dysfunctions. Curr Med Chem 15(18):1851–1862CrossRefPubMed

17.

Morgan SA, Bringolf JB, Seidel ER (2008) Visfatin expression is elevated in normal human pregnancy. Peptides 29(8):1382–1389. https://doi.org/10.1016/j.peptides.2008.04.010 Epub Apr 26 CrossRefPubMed

18.

Chan TF, Chen YL, Lee CH et al (2006) Decreased plasma visfatin concentrations in women with gestational diabetes mellitus. J Soc Gynecol Investig 13(5):364–367CrossRefPubMed

19.

Fukuhara A, Matsuda M, Nishizawa M et al (2005) Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307(5708):426–430 Epub 2004 Dec 16 CrossRefPubMed

20.

Lopez-Bermejo A, Chico-Julia B, Fernandez-Balsells M et al (2006) Serum visfatin increases with progressive beta-cell deterioration. Diabetes 55(10):2871–2875CrossRefPubMed

21.

Ferreira AF, Rezende JC, Vaikousi E, Akolekar R, Nicolaides KH (2011) Maternal serum visfatin at 11-13 weeks of gestation in gestational diabetes mellitus. Clin Chem 57(4):609–613. https://doi.org/10.1373/clinchem.2010.159806 Epub 2011 Feb 15 CrossRefPubMed

22.

Zahorska-Markiewicz B, Olszanecka-Glinianowicz M, Janowska J et al (2007) Serum concentration of visfatin in obese women. Metabolism. 56(8):1131–1134CrossRefPubMed

23.

24.

Derosa G, Fogari E, D’Angelo A et al (2013) Adipocytokine levels in obese and non-obese subjects: an observational study. Inflammation. 36:914–920CrossRefPubMed

25.

Pagano C, Pilon C, Olivieri M et al (2006) Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab 91(8):3165–3170CrossRefPubMed

26.

Krzyzanowska K, Krugluger W, Mittermayer F et al (2006) Increased visfatin concentrations in women with gestational diabetes mellitus. Clin Sci (Lond). 110(5):605–609CrossRefPubMed

27.

Telejko B, Kuzmicki M, Zonenberg A et al (2009) Visfatin in gestational diabetes: serum level and mRNA expression in fat and placental tissue. Diabetes Res Clin Pract 84(1):68–75. https://doi.org/10.1016/j.diabres.2008.12.017 Epub 9 Jan 30 CrossRefPubMed

28.

Tan BK, Adya R, Randeva HS (2010) Omentin: a novel link between inflammation, diabesity, and cardiovascular disease. Trends Cardiovasc Med 20(5):143–148. https://doi.org/10.1016/j.tcm.2010.12.002 CrossRefPubMed

29.

Tsuji S, Uehori J, Matsumoto M et al (2001) Human intelectin is a novel soluble lectin that recognizes galactofuranose in carbohydrate chains of bacterial cell wall. J Biol Chem 276(26):23456–23463CrossRefPubMed

30.

Maenhaut N, Van de Voorde J (2011) Regulation of vascular tone by adipocytes. BMC Med 9:25CrossRefPubMedPubMedCentral

31.

Tan BK, Adya R, Farhatullah S et al (2008) Omentin-1, a novel adipokine, is decreased in overweight insulin-resistant women with polycystic ovary syndrome: ex vivo and in vivo regulation of omentin-1 by insulin and glucose. Diabetes 57(4):801–808CrossRefPubMed

32.

de Souza Batista CM, Yang RZ, Lee MJ et al (2007) Omentin plasma levels and gene expression are decreased in obesity. Diabetes 56(6):1655–1661 Epub 2007 Feb 28 CrossRefPubMed

33.

Barker G, Lim R, Georgiou HM, Lappas M (2012) Omentin-1 is decreased in maternal plasma, placenta and adipose tissue of women with pre-existing obesity. PLoS ONE 7(8):e42943CrossRefPubMedPubMedCentral

34.

Lewandowski K, Nadel I, Lewinski A et al (2010) Positive correlation between serum omentin and thrombospondin-1 in gestational diabetes despite lack of correlation with insulin resistance indices. Ginekol Pol 81(12):907–912PubMed

35.

Lappas M, Yee K, Permezel M, Rice GE (2005) Release and regulation of leptin, resistin and adiponectin from human placenta, fetal membranes, and maternal adipose tissue and skeletal muscle from normal and gestational diabetes mellitus-complicated pregnancies. J Endocrinol 186(3):457–465CrossRefPubMed

36.

White P (1949) Pregnancy complicating diabetes. Am J Med 7(5):609–616CrossRefPubMed

37.

Abell SK, De Courten B, Boyle JA, Teede HJ (2015) Inflammatory and other biomarkers: role in pathophysiology and prediction of gestational diabetes mellitus. Int J Mol Sci 16(6):13442–13473CrossRefPubMedPubMedCentral

38.

Sunsaneevithayakul P, Boriboohirunsarn D, Sutanthavibul A et al (2003) Risk factor-based selective screening program for gestational diabetes mellitus in Siriraj Hospital: result from clinical practice guideline. J Med Assoc Thail 86(8):708–714

39.

Cleal JK, Day P, Hanson MA, Lewis RM (2009) Measurement of housekeeping genes in human placenta. Placenta 30(11):1002–1003CrossRefPubMed

40.

Coskun A, Ozkaya M, Kiran G, Kilinc M, Arikan DC (2010) Plasma visfatin levels in pregnant women with normal glucose tolerance, gestational diabetes and pre-gestational diabetes mellitus. J Matern Fetal Neonatal Med. 23(9):1014–1018CrossRefPubMed

41.

Gabbe SG (1981) Diabetes mellitus in pregnancy: have all the problems been solved? Am J Med 70(3):613–618CrossRefPubMed

42.

Shokry E, Marchioro L, Uhl O et al (2019) Impact of maternal BMI and gestational diabetes mellitus on maternal and cord blood metabolome: results from the PREOBE cohort study. Acta Diabetol 56(4):421–430CrossRefPubMed

43.

Haider DG, Schaller G, Kapiotis S, Maier C, Luger A, Wolzt M (2006) The release of the adipocytokine visfatin is regulated by glucose and insulin. Diabetologia 49(8):1909–1914CrossRefPubMed

44.

Haider DG, Schindler K, Schaller G, Prager G, Wolzt M, Ludvik B (2006) Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab 91(4):1578–1581CrossRefPubMed

45.

Szamatowicz J, Kuzmicki M, Telejko B et al (2009) Serum visfatin concentration is elevated in pregnant women irrespectively of the presence of gestational diabetes. Ginekol Pol 80(1):14–18PubMed

46.

Akturk M, Altinova AE, Mert I et al (2008) Visfatin concentration is decreased in women with gestational diabetes mellitus in the third trimester. J Endocrinol Invest 31(7):610–613CrossRefPubMed

47.

Nway NC, Sitticharoon C, Chatree S, Maikaew P (2016) Correlations between the expression of the insulin sensitizing hormones, adiponectin, visfatin, and omentin, and the appetite regulatory hormone, neuropeptide Y and its receptors in subcutaneous and visceral adipose tissues. Obes Res Clin Pract. 10(3):256–263CrossRefPubMed

48.

Bergmann K, Sypniewska G (2013) Diabetes as a complication of adipose tissue dysfunction. Is there a role for potential new biomarkers? Clin Chem Lab Med. 51(1):177–185CrossRefPubMed

49.

Kabir M, Catalano KJ, Ananthnarayan S et al (2005) Molecular evidence supporting the portal theory: a causative link between visceral adiposity and hepatic insulin resistance. Am J Physiol Endocrinol Metab 288(2):E454–E461CrossRefPubMed

50.

Simons PJ, van den Pangaart PS, Aerts JM, Boon L (2007) Pro-inflammatory delipidizing cytokines reduce adiponectin secretion from human adipocytes without affecting adiponectin oligomerization. J Endocrinol 192(2):289–299CrossRefPubMed

51.

Mohlig M, Wegewitz U, Osterhoff M et al (2002) Insulin decreases human adiponectin plasma levels. Horm Metab Res 34(11–12):655–658CrossRefPubMed

52.

Hivert M-F, Sun Q, Shrader P, Mantzoros CS, Meigs JB, Hu FB (2011) Higher adiponectin levels predict greater weight gain in healthy women in the Nurses’ Health Study. Obesity (Silver Spring, Md). 19(2):409–415CrossRef

53.

Shoelson SE, Herrero L, Naaz A (2007) Obesity, inflammation, and insulin resistance. Gastroenterology 132(6):2169–2180CrossRefPubMed

54.

55.

Zheng J, Xiao X, Zhang Q et al (2014) Correlation of high-molecular-weight adiponectin and leptin concentrations with anthropometric parameters and insulin sensitivity in newborns. Int J Endocrinol 2014:435376PubMedPubMedCentral

Titel: Placental expressions and serum levels of adiponectin, visfatin, and omentin in GDM
verfasst von: Xaynaly Souvannavong-Vilivong
Chantacha Sitticharoon
Roongrit Klinjampa
Issarawan Keadkraichaiwat
Chanakarn Sripong
Saimai Chatree
Rungnapa Sririwichitchai
Tripop Lertbunnaphong
Publikationsdatum: 10.05.2019
Verlag: Springer Milan
Erschienen in: Acta Diabetologica / Ausgabe 10/2019
Print ISSN: 0940-5429
Elektronische ISSN: 1432-5233
DOI: https://doi.org/10.1007/s00592-019-01355-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

11.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Im Battle of Experts traten zwei Experten auf dem Diabeteskongress gegeneinander an: Die eine vertrat die Auffassung „Sport statt Spritze“ bei Adipositas und Typ-2-Diabetes, der andere forderte „Spritze statt Sport!“ Am Ende waren sie sich aber einig: Die Kombination aus beidem erzielt die besten Ergebnisse.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Placental expressions and serum levels of adiponectin, visfatin, and omentin in GDM

Abstract